Global Drug-Resistant Tuberculosis Treatment Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Drug-Resistant Tuberculosis Treatment market size was valued at US$ 2393 million in 2024 and is forecast to a readjusted size of USD 3393 million by 2031 with a CAGR of 5.2% during review period.
Drug-resistant tuberculosis (DR-TB) treatment refers to the medical interventions and therapies used to manage and combat tuberculosis (TB) infections caused by strains of the Mycobacterium tuberculosis bacteria that are resistant to one or more of the standard anti-TB drugs. DR-TB is a significant global health concern because it poses challenges for effective TB control and requires more complex and prolonged treatment regimens compared to drug-susceptible TB. There are different categories of DR-TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), each with its own treatment protocols.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Drug-Resistant Tuberculosis Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Drug-Resistant Tuberculosis Treatment market size and forecasts, in consumption value ($ Million), 2020-2031
Global Drug-Resistant Tuberculosis Treatment market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Drug-Resistant Tuberculosis Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Drug-Resistant Tuberculosis Treatment market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drug-Resistant Tuberculosis Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drug-Resistant Tuberculosis Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services Inc., Macleods Pharmaceuticals Ltd, Pfizer Inc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Drug-Resistant Tuberculosis Treatment market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Drug-Resistant Tuberculosis Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Drug-Resistant Tuberculosis Treatment, with revenue, gross margin, and global market share of Drug-Resistant Tuberculosis Treatment from 2020 to 2025.
Chapter 3, the Drug-Resistant Tuberculosis Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Drug-Resistant Tuberculosis Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Drug-Resistant Tuberculosis Treatment.
Chapter 13, to describe Drug-Resistant Tuberculosis Treatment research findings and conclusion.
Drug-resistant tuberculosis (DR-TB) treatment refers to the medical interventions and therapies used to manage and combat tuberculosis (TB) infections caused by strains of the Mycobacterium tuberculosis bacteria that are resistant to one or more of the standard anti-TB drugs. DR-TB is a significant global health concern because it poses challenges for effective TB control and requires more complex and prolonged treatment regimens compared to drug-susceptible TB. There are different categories of DR-TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), each with its own treatment protocols.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Drug-Resistant Tuberculosis Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Drug-Resistant Tuberculosis Treatment market size and forecasts, in consumption value ($ Million), 2020-2031
Global Drug-Resistant Tuberculosis Treatment market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Drug-Resistant Tuberculosis Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Drug-Resistant Tuberculosis Treatment market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drug-Resistant Tuberculosis Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drug-Resistant Tuberculosis Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services Inc., Macleods Pharmaceuticals Ltd, Pfizer Inc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Drug-Resistant Tuberculosis Treatment market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- First-Line Anti-TB Drugs
- Second-Line Anti-TB Drugs
- Others
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
- Sanofi
- Novartis AG
- Endo International plc
- CMP Pharma
- STI Pharma LLC
- Akorn Incorporated
- Lupin
- Johnson & Johnson Services Inc.
- Macleods Pharmaceuticals Ltd
- Pfizer Inc
- Hikma Pharmaceuticals PLC
- Lannett
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- Fresenius Kabi AG
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Drug-Resistant Tuberculosis Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Drug-Resistant Tuberculosis Treatment, with revenue, gross margin, and global market share of Drug-Resistant Tuberculosis Treatment from 2020 to 2025.
Chapter 3, the Drug-Resistant Tuberculosis Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Drug-Resistant Tuberculosis Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Drug-Resistant Tuberculosis Treatment.
Chapter 13, to describe Drug-Resistant Tuberculosis Treatment research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Drug-Resistant Tuberculosis Treatment by Type
1.3.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type in 2024
1.3.3 First-Line Anti-TB Drugs
1.3.4 Second-Line Anti-TB Drugs
1.3.5 Others
1.4 Global Drug-Resistant Tuberculosis Treatment Market by Application
1.4.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital Pharmacy
1.4.3 Online Pharmacy
1.4.4 Retail Pharmacy
1.4.5 Others
1.5 Global Drug-Resistant Tuberculosis Treatment Market Size & Forecast
1.6 Global Drug-Resistant Tuberculosis Treatment Market Size and Forecast by Region
1.6.1 Global Drug-Resistant Tuberculosis Treatment Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Drug-Resistant Tuberculosis Treatment Market Size by Region, (2020-2031)
1.6.3 North America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
1.6.4 Europe Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
1.6.6 South America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
2.1.4 Sanofi Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Novartis AG
2.2.1 Novartis AG Details
2.2.2 Novartis AG Major Business
2.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
2.2.4 Novartis AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Novartis AG Recent Developments and Future Plans
2.3 Endo International plc
2.3.1 Endo International plc Details
2.3.2 Endo International plc Major Business
2.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
2.3.4 Endo International plc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Endo International plc Recent Developments and Future Plans
2.4 CMP Pharma
2.4.1 CMP Pharma Details
2.4.2 CMP Pharma Major Business
2.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
2.4.4 CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 CMP Pharma Recent Developments and Future Plans
2.5 STI Pharma LLC
2.5.1 STI Pharma LLC Details
2.5.2 STI Pharma LLC Major Business
2.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
2.5.4 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 STI Pharma LLC Recent Developments and Future Plans
2.6 Akorn Incorporated
2.6.1 Akorn Incorporated Details
2.6.2 Akorn Incorporated Major Business
2.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
2.6.4 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Akorn Incorporated Recent Developments and Future Plans
2.7 Lupin
2.7.1 Lupin Details
2.7.2 Lupin Major Business
2.7.3 Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
2.7.4 Lupin Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Lupin Recent Developments and Future Plans
2.8 Johnson & Johnson Services Inc.
2.8.1 Johnson & Johnson Services Inc. Details
2.8.2 Johnson & Johnson Services Inc. Major Business
2.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
2.8.4 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Johnson & Johnson Services Inc. Recent Developments and Future Plans
2.9 Macleods Pharmaceuticals Ltd
2.9.1 Macleods Pharmaceuticals Ltd Details
2.9.2 Macleods Pharmaceuticals Ltd Major Business
2.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
2.9.4 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
2.10 Pfizer Inc
2.10.1 Pfizer Inc Details
2.10.2 Pfizer Inc Major Business
2.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
2.10.4 Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Pfizer Inc Recent Developments and Future Plans
2.11 Hikma Pharmaceuticals PLC
2.11.1 Hikma Pharmaceuticals PLC Details
2.11.2 Hikma Pharmaceuticals PLC Major Business
2.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
2.11.4 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Hikma Pharmaceuticals PLC Recent Developments and Future Plans
2.12 Lannett
2.12.1 Lannett Details
2.12.2 Lannett Major Business
2.12.3 Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
2.12.4 Lannett Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Lannett Recent Developments and Future Plans
2.13 Mylan N.V.
2.13.1 Mylan N.V. Details
2.13.2 Mylan N.V. Major Business
2.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
2.13.4 Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Mylan N.V. Recent Developments and Future Plans
2.14 Teva Pharmaceutical Industries Ltd
2.14.1 Teva Pharmaceutical Industries Ltd Details
2.14.2 Teva Pharmaceutical Industries Ltd Major Business
2.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
2.14.4 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.15 Fresenius Kabi AG
2.15.1 Fresenius Kabi AG Details
2.15.2 Fresenius Kabi AG Major Business
2.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
2.15.4 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Fresenius Kabi AG Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Drug-Resistant Tuberculosis Treatment Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Drug-Resistant Tuberculosis Treatment by Company Revenue
3.2.2 Top 3 Drug-Resistant Tuberculosis Treatment Players Market Share in 2024
3.2.3 Top 6 Drug-Resistant Tuberculosis Treatment Players Market Share in 2024
3.3 Drug-Resistant Tuberculosis Treatment Market: Overall Company Footprint Analysis
3.3.1 Drug-Resistant Tuberculosis Treatment Market: Region Footprint
3.3.2 Drug-Resistant Tuberculosis Treatment Market: Company Product Type Footprint
3.3.3 Drug-Resistant Tuberculosis Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Drug-Resistant Tuberculosis Treatment Consumption Value and Market Share by Type (2020-2025)
4.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2025)
5.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
6.2 North America Drug-Resistant Tuberculosis Treatment Market Size by Application (2020-2031)
6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country
6.3.1 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2031)
6.3.2 United States Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
6.3.3 Canada Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
6.3.4 Mexico Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
7.2 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2031)
7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country
7.3.1 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2031)
7.3.2 Germany Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7.3.3 France Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7.3.5 Russia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7.3.6 Italy Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region
8.3.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2020-2031)
8.3.2 China Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.3 Japan Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.4 South Korea Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.5 India Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.7 Australia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
9.2 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2031)
9.3 South America Drug-Resistant Tuberculosis Treatment Market Size by Country
9.3.1 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2031)
9.3.2 Brazil Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
9.3.3 Argentina Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country
10.3.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2031)
10.3.2 Turkey Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
10.3.4 UAE Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Drug-Resistant Tuberculosis Treatment Market Drivers
11.2 Drug-Resistant Tuberculosis Treatment Market Restraints
11.3 Drug-Resistant Tuberculosis Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Drug-Resistant Tuberculosis Treatment Industry Chain
12.2 Drug-Resistant Tuberculosis Treatment Upstream Analysis
12.3 Drug-Resistant Tuberculosis Treatment Midstream Analysis
12.4 Drug-Resistant Tuberculosis Treatment Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Drug-Resistant Tuberculosis Treatment by Type
1.3.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type in 2024
1.3.3 First-Line Anti-TB Drugs
1.3.4 Second-Line Anti-TB Drugs
1.3.5 Others
1.4 Global Drug-Resistant Tuberculosis Treatment Market by Application
1.4.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital Pharmacy
1.4.3 Online Pharmacy
1.4.4 Retail Pharmacy
1.4.5 Others
1.5 Global Drug-Resistant Tuberculosis Treatment Market Size & Forecast
1.6 Global Drug-Resistant Tuberculosis Treatment Market Size and Forecast by Region
1.6.1 Global Drug-Resistant Tuberculosis Treatment Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Drug-Resistant Tuberculosis Treatment Market Size by Region, (2020-2031)
1.6.3 North America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
1.6.4 Europe Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
1.6.6 South America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
2.1.4 Sanofi Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Novartis AG
2.2.1 Novartis AG Details
2.2.2 Novartis AG Major Business
2.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
2.2.4 Novartis AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Novartis AG Recent Developments and Future Plans
2.3 Endo International plc
2.3.1 Endo International plc Details
2.3.2 Endo International plc Major Business
2.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
2.3.4 Endo International plc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Endo International plc Recent Developments and Future Plans
2.4 CMP Pharma
2.4.1 CMP Pharma Details
2.4.2 CMP Pharma Major Business
2.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
2.4.4 CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 CMP Pharma Recent Developments and Future Plans
2.5 STI Pharma LLC
2.5.1 STI Pharma LLC Details
2.5.2 STI Pharma LLC Major Business
2.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
2.5.4 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 STI Pharma LLC Recent Developments and Future Plans
2.6 Akorn Incorporated
2.6.1 Akorn Incorporated Details
2.6.2 Akorn Incorporated Major Business
2.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
2.6.4 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Akorn Incorporated Recent Developments and Future Plans
2.7 Lupin
2.7.1 Lupin Details
2.7.2 Lupin Major Business
2.7.3 Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
2.7.4 Lupin Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Lupin Recent Developments and Future Plans
2.8 Johnson & Johnson Services Inc.
2.8.1 Johnson & Johnson Services Inc. Details
2.8.2 Johnson & Johnson Services Inc. Major Business
2.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
2.8.4 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Johnson & Johnson Services Inc. Recent Developments and Future Plans
2.9 Macleods Pharmaceuticals Ltd
2.9.1 Macleods Pharmaceuticals Ltd Details
2.9.2 Macleods Pharmaceuticals Ltd Major Business
2.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
2.9.4 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
2.10 Pfizer Inc
2.10.1 Pfizer Inc Details
2.10.2 Pfizer Inc Major Business
2.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
2.10.4 Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Pfizer Inc Recent Developments and Future Plans
2.11 Hikma Pharmaceuticals PLC
2.11.1 Hikma Pharmaceuticals PLC Details
2.11.2 Hikma Pharmaceuticals PLC Major Business
2.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
2.11.4 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Hikma Pharmaceuticals PLC Recent Developments and Future Plans
2.12 Lannett
2.12.1 Lannett Details
2.12.2 Lannett Major Business
2.12.3 Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
2.12.4 Lannett Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Lannett Recent Developments and Future Plans
2.13 Mylan N.V.
2.13.1 Mylan N.V. Details
2.13.2 Mylan N.V. Major Business
2.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
2.13.4 Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Mylan N.V. Recent Developments and Future Plans
2.14 Teva Pharmaceutical Industries Ltd
2.14.1 Teva Pharmaceutical Industries Ltd Details
2.14.2 Teva Pharmaceutical Industries Ltd Major Business
2.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
2.14.4 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.15 Fresenius Kabi AG
2.15.1 Fresenius Kabi AG Details
2.15.2 Fresenius Kabi AG Major Business
2.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
2.15.4 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Fresenius Kabi AG Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Drug-Resistant Tuberculosis Treatment Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Drug-Resistant Tuberculosis Treatment by Company Revenue
3.2.2 Top 3 Drug-Resistant Tuberculosis Treatment Players Market Share in 2024
3.2.3 Top 6 Drug-Resistant Tuberculosis Treatment Players Market Share in 2024
3.3 Drug-Resistant Tuberculosis Treatment Market: Overall Company Footprint Analysis
3.3.1 Drug-Resistant Tuberculosis Treatment Market: Region Footprint
3.3.2 Drug-Resistant Tuberculosis Treatment Market: Company Product Type Footprint
3.3.3 Drug-Resistant Tuberculosis Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Drug-Resistant Tuberculosis Treatment Consumption Value and Market Share by Type (2020-2025)
4.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2025)
5.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
6.2 North America Drug-Resistant Tuberculosis Treatment Market Size by Application (2020-2031)
6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country
6.3.1 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2031)
6.3.2 United States Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
6.3.3 Canada Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
6.3.4 Mexico Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
7.2 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2031)
7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country
7.3.1 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2031)
7.3.2 Germany Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7.3.3 France Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7.3.5 Russia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
7.3.6 Italy Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region
8.3.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2020-2031)
8.3.2 China Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.3 Japan Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.4 South Korea Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.5 India Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
8.3.7 Australia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
9.2 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2031)
9.3 South America Drug-Resistant Tuberculosis Treatment Market Size by Country
9.3.1 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2031)
9.3.2 Brazil Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
9.3.3 Argentina Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country
10.3.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2031)
10.3.2 Turkey Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
10.3.4 UAE Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Drug-Resistant Tuberculosis Treatment Market Drivers
11.2 Drug-Resistant Tuberculosis Treatment Market Restraints
11.3 Drug-Resistant Tuberculosis Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Drug-Resistant Tuberculosis Treatment Industry Chain
12.2 Drug-Resistant Tuberculosis Treatment Upstream Analysis
12.3 Drug-Resistant Tuberculosis Treatment Midstream Analysis
12.4 Drug-Resistant Tuberculosis Treatment Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Sanofi Company Information, Head Office, and Major Competitors
Table 6. Sanofi Major Business
Table 7. Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 8. Sanofi Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Sanofi Recent Developments and Future Plans
Table 10. Novartis AG Company Information, Head Office, and Major Competitors
Table 11. Novartis AG Major Business
Table 12. Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 13. Novartis AG Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Novartis AG Recent Developments and Future Plans
Table 15. Endo International plc Company Information, Head Office, and Major Competitors
Table 16. Endo International plc Major Business
Table 17. Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 18. Endo International plc Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. CMP Pharma Company Information, Head Office, and Major Competitors
Table 20. CMP Pharma Major Business
Table 21. CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 22. CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. CMP Pharma Recent Developments and Future Plans
Table 24. STI Pharma LLC Company Information, Head Office, and Major Competitors
Table 25. STI Pharma LLC Major Business
Table 26. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 27. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. STI Pharma LLC Recent Developments and Future Plans
Table 29. Akorn Incorporated Company Information, Head Office, and Major Competitors
Table 30. Akorn Incorporated Major Business
Table 31. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 32. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Akorn Incorporated Recent Developments and Future Plans
Table 34. Lupin Company Information, Head Office, and Major Competitors
Table 35. Lupin Major Business
Table 36. Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 37. Lupin Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Lupin Recent Developments and Future Plans
Table 39. Johnson & Johnson Services Inc. Company Information, Head Office, and Major Competitors
Table 40. Johnson & Johnson Services Inc. Major Business
Table 41. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 42. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Johnson & Johnson Services Inc. Recent Developments and Future Plans
Table 44. Macleods Pharmaceuticals Ltd Company Information, Head Office, and Major Competitors
Table 45. Macleods Pharmaceuticals Ltd Major Business
Table 46. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 47. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
Table 49. Pfizer Inc Company Information, Head Office, and Major Competitors
Table 50. Pfizer Inc Major Business
Table 51. Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 52. Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Pfizer Inc Recent Developments and Future Plans
Table 54. Hikma Pharmaceuticals PLC Company Information, Head Office, and Major Competitors
Table 55. Hikma Pharmaceuticals PLC Major Business
Table 56. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 57. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Hikma Pharmaceuticals PLC Recent Developments and Future Plans
Table 59. Lannett Company Information, Head Office, and Major Competitors
Table 60. Lannett Major Business
Table 61. Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 62. Lannett Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Lannett Recent Developments and Future Plans
Table 64. Mylan N.V. Company Information, Head Office, and Major Competitors
Table 65. Mylan N.V. Major Business
Table 66. Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 67. Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Mylan N.V. Recent Developments and Future Plans
Table 69. Teva Pharmaceutical Industries Ltd Company Information, Head Office, and Major Competitors
Table 70. Teva Pharmaceutical Industries Ltd Major Business
Table 71. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 72. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Table 74. Fresenius Kabi AG Company Information, Head Office, and Major Competitors
Table 75. Fresenius Kabi AG Major Business
Table 76. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 77. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 78. Fresenius Kabi AG Recent Developments and Future Plans
Table 79. Global Drug-Resistant Tuberculosis Treatment Revenue (USD Million) by Players (2020-2025)
Table 80. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players (2020-2025)
Table 81. Breakdown of Drug-Resistant Tuberculosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 82. Market Position of Players in Drug-Resistant Tuberculosis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 83. Head Office of Key Drug-Resistant Tuberculosis Treatment Players
Table 84. Drug-Resistant Tuberculosis Treatment Market: Company Product Type Footprint
Table 85. Drug-Resistant Tuberculosis Treatment Market: Company Product Application Footprint
Table 86. Drug-Resistant Tuberculosis Treatment New Market Entrants and Barriers to Market Entry
Table 87. Drug-Resistant Tuberculosis Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 88. Global Drug-Resistant Tuberculosis Treatment Consumption Value (USD Million) by Type (2020-2025)
Table 89. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Type (2020-2025)
Table 90. Global Drug-Resistant Tuberculosis Treatment Consumption Value Forecast by Type (2026-2031)
Table 91. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025)
Table 92. Global Drug-Resistant Tuberculosis Treatment Consumption Value Forecast by Application (2026-2031)
Table 93. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 94. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 95. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 96. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 97. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2025) & (USD Million)
Table 98. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2026-2031) & (USD Million)
Table 99. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 100. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 101. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 102. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 103. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2025) & (USD Million)
Table 104. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2026-2031) & (USD Million)
Table 105. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 106. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 107. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 108. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 109. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2020-2025) & (USD Million)
Table 110. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2026-2031) & (USD Million)
Table 111. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 112. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 113. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 114. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 115. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2025) & (USD Million)
Table 116. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2026-2031) & (USD Million)
Table 117. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 118. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 119. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 120. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 121. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2025) & (USD Million)
Table 122. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2026-2031) & (USD Million)
Table 123. Global Key Players of Drug-Resistant Tuberculosis Treatment Upstream (Raw Materials)
Table 124. Global Drug-Resistant Tuberculosis Treatment Typical Customers
Table 1. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Sanofi Company Information, Head Office, and Major Competitors
Table 6. Sanofi Major Business
Table 7. Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 8. Sanofi Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Sanofi Recent Developments and Future Plans
Table 10. Novartis AG Company Information, Head Office, and Major Competitors
Table 11. Novartis AG Major Business
Table 12. Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 13. Novartis AG Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Novartis AG Recent Developments and Future Plans
Table 15. Endo International plc Company Information, Head Office, and Major Competitors
Table 16. Endo International plc Major Business
Table 17. Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 18. Endo International plc Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. CMP Pharma Company Information, Head Office, and Major Competitors
Table 20. CMP Pharma Major Business
Table 21. CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 22. CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. CMP Pharma Recent Developments and Future Plans
Table 24. STI Pharma LLC Company Information, Head Office, and Major Competitors
Table 25. STI Pharma LLC Major Business
Table 26. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 27. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. STI Pharma LLC Recent Developments and Future Plans
Table 29. Akorn Incorporated Company Information, Head Office, and Major Competitors
Table 30. Akorn Incorporated Major Business
Table 31. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 32. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Akorn Incorporated Recent Developments and Future Plans
Table 34. Lupin Company Information, Head Office, and Major Competitors
Table 35. Lupin Major Business
Table 36. Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 37. Lupin Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Lupin Recent Developments and Future Plans
Table 39. Johnson & Johnson Services Inc. Company Information, Head Office, and Major Competitors
Table 40. Johnson & Johnson Services Inc. Major Business
Table 41. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 42. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Johnson & Johnson Services Inc. Recent Developments and Future Plans
Table 44. Macleods Pharmaceuticals Ltd Company Information, Head Office, and Major Competitors
Table 45. Macleods Pharmaceuticals Ltd Major Business
Table 46. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 47. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
Table 49. Pfizer Inc Company Information, Head Office, and Major Competitors
Table 50. Pfizer Inc Major Business
Table 51. Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 52. Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Pfizer Inc Recent Developments and Future Plans
Table 54. Hikma Pharmaceuticals PLC Company Information, Head Office, and Major Competitors
Table 55. Hikma Pharmaceuticals PLC Major Business
Table 56. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 57. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Hikma Pharmaceuticals PLC Recent Developments and Future Plans
Table 59. Lannett Company Information, Head Office, and Major Competitors
Table 60. Lannett Major Business
Table 61. Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 62. Lannett Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Lannett Recent Developments and Future Plans
Table 64. Mylan N.V. Company Information, Head Office, and Major Competitors
Table 65. Mylan N.V. Major Business
Table 66. Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 67. Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Mylan N.V. Recent Developments and Future Plans
Table 69. Teva Pharmaceutical Industries Ltd Company Information, Head Office, and Major Competitors
Table 70. Teva Pharmaceutical Industries Ltd Major Business
Table 71. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 72. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Table 74. Fresenius Kabi AG Company Information, Head Office, and Major Competitors
Table 75. Fresenius Kabi AG Major Business
Table 76. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 77. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 78. Fresenius Kabi AG Recent Developments and Future Plans
Table 79. Global Drug-Resistant Tuberculosis Treatment Revenue (USD Million) by Players (2020-2025)
Table 80. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players (2020-2025)
Table 81. Breakdown of Drug-Resistant Tuberculosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 82. Market Position of Players in Drug-Resistant Tuberculosis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 83. Head Office of Key Drug-Resistant Tuberculosis Treatment Players
Table 84. Drug-Resistant Tuberculosis Treatment Market: Company Product Type Footprint
Table 85. Drug-Resistant Tuberculosis Treatment Market: Company Product Application Footprint
Table 86. Drug-Resistant Tuberculosis Treatment New Market Entrants and Barriers to Market Entry
Table 87. Drug-Resistant Tuberculosis Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 88. Global Drug-Resistant Tuberculosis Treatment Consumption Value (USD Million) by Type (2020-2025)
Table 89. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Type (2020-2025)
Table 90. Global Drug-Resistant Tuberculosis Treatment Consumption Value Forecast by Type (2026-2031)
Table 91. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025)
Table 92. Global Drug-Resistant Tuberculosis Treatment Consumption Value Forecast by Application (2026-2031)
Table 93. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 94. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 95. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 96. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 97. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2025) & (USD Million)
Table 98. North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2026-2031) & (USD Million)
Table 99. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 100. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 101. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 102. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 103. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2025) & (USD Million)
Table 104. Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2026-2031) & (USD Million)
Table 105. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 106. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 107. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 108. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 109. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2020-2025) & (USD Million)
Table 110. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2026-2031) & (USD Million)
Table 111. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 112. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 113. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 114. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 115. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2025) & (USD Million)
Table 116. South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2026-2031) & (USD Million)
Table 117. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2020-2025) & (USD Million)
Table 118. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2026-2031) & (USD Million)
Table 119. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2020-2025) & (USD Million)
Table 120. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2026-2031) & (USD Million)
Table 121. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2020-2025) & (USD Million)
Table 122. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2026-2031) & (USD Million)
Table 123. Global Key Players of Drug-Resistant Tuberculosis Treatment Upstream (Raw Materials)
Table 124. Global Drug-Resistant Tuberculosis Treatment Typical Customers
LIST OF FIGURES
Figure 1. Drug-Resistant Tuberculosis Treatment Picture
Figure 2. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type in 2024
Figure 4. First-Line Anti-TB Drugs
Figure 5. Second-Line Anti-TB Drugs
Figure 6. Others
Figure 7. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 8. Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application in 2024
Figure 9. Hospital Pharmacy Picture
Figure 10. Online Pharmacy Picture
Figure 11. Retail Pharmacy Picture
Figure 12. Others Picture
Figure 13. Global Drug-Resistant Tuberculosis Treatment Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Drug-Resistant Tuberculosis Treatment Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Market Drug-Resistant Tuberculosis Treatment Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 16. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region (2020-2031)
Figure 17. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region in 2024
Figure 18. North America Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 19. Europe Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 20. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 21. South America Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 22. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players in 2024
Figure 25. Drug-Resistant Tuberculosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 26. Market Share of Drug-Resistant Tuberculosis Treatment by Player Revenue in 2024
Figure 27. Top 3 Drug-Resistant Tuberculosis Treatment Players Market Share in 2024
Figure 28. Top 6 Drug-Resistant Tuberculosis Treatment Players Market Share in 2024
Figure 29. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Type (2020-2025)
Figure 30. Global Drug-Resistant Tuberculosis Treatment Market Share Forecast by Type (2026-2031)
Figure 31. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Application (2020-2025)
Figure 32. Global Drug-Resistant Tuberculosis Treatment Market Share Forecast by Application (2026-2031)
Figure 33. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 34. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 35. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2020-2031)
Figure 36. United States Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 37. Canada Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 38. Mexico Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 39. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 40. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 41. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2020-2031)
Figure 42. Germany Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 43. France Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 44. United Kingdom Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 45. Russia Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 46. Italy Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 47. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 48. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 49. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region (2020-2031)
Figure 50. China Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 51. Japan Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 52. South Korea Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 53. India Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 54. Southeast Asia Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 55. Australia Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 56. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 57. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 58. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2020-2031)
Figure 59. Brazil Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 60. Argentina Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 61. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 62. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 63. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2020-2031)
Figure 64. Turkey Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 65. Saudi Arabia Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 66. UAE Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 67. Drug-Resistant Tuberculosis Treatment Market Drivers
Figure 68. Drug-Resistant Tuberculosis Treatment Market Restraints
Figure 69. Drug-Resistant Tuberculosis Treatment Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Drug-Resistant Tuberculosis Treatment Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Drug-Resistant Tuberculosis Treatment Picture
Figure 2. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type in 2024
Figure 4. First-Line Anti-TB Drugs
Figure 5. Second-Line Anti-TB Drugs
Figure 6. Others
Figure 7. Global Drug-Resistant Tuberculosis Treatment Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 8. Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application in 2024
Figure 9. Hospital Pharmacy Picture
Figure 10. Online Pharmacy Picture
Figure 11. Retail Pharmacy Picture
Figure 12. Others Picture
Figure 13. Global Drug-Resistant Tuberculosis Treatment Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Drug-Resistant Tuberculosis Treatment Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Market Drug-Resistant Tuberculosis Treatment Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 16. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region (2020-2031)
Figure 17. Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region in 2024
Figure 18. North America Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 19. Europe Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 20. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 21. South America Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 22. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players in 2024
Figure 25. Drug-Resistant Tuberculosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 26. Market Share of Drug-Resistant Tuberculosis Treatment by Player Revenue in 2024
Figure 27. Top 3 Drug-Resistant Tuberculosis Treatment Players Market Share in 2024
Figure 28. Top 6 Drug-Resistant Tuberculosis Treatment Players Market Share in 2024
Figure 29. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Type (2020-2025)
Figure 30. Global Drug-Resistant Tuberculosis Treatment Market Share Forecast by Type (2026-2031)
Figure 31. Global Drug-Resistant Tuberculosis Treatment Consumption Value Share by Application (2020-2025)
Figure 32. Global Drug-Resistant Tuberculosis Treatment Market Share Forecast by Application (2026-2031)
Figure 33. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 34. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 35. North America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2020-2031)
Figure 36. United States Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 37. Canada Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 38. Mexico Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 39. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 40. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 41. Europe Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2020-2031)
Figure 42. Germany Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 43. France Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 44. United Kingdom Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 45. Russia Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 46. Italy Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 47. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 48. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 49. Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Region (2020-2031)
Figure 50. China Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 51. Japan Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 52. South Korea Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 53. India Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 54. Southeast Asia Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 55. Australia Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 56. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 57. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 58. South America Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2020-2031)
Figure 59. Brazil Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 60. Argentina Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 61. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type (2020-2031)
Figure 62. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2020-2031)
Figure 63. Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Country (2020-2031)
Figure 64. Turkey Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 65. Saudi Arabia Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 66. UAE Drug-Resistant Tuberculosis Treatment Consumption Value (2020-2031) & (USD Million)
Figure 67. Drug-Resistant Tuberculosis Treatment Market Drivers
Figure 68. Drug-Resistant Tuberculosis Treatment Market Restraints
Figure 69. Drug-Resistant Tuberculosis Treatment Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Drug-Resistant Tuberculosis Treatment Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
